1921
Volume 79, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The efficacy of a recombinant subunit West Nile (WN) vaccine candidate was determined in a hamster model of encephalitis. Animals included young, aged, and immunocompromised animals in an effort to simulate key groups at risk of WN virus–induced disease. Groups of aged (12 month old), weanling, and adult hamsters rendered leukopenic after immunization were immunized subcutaneously with a WN virus recombinant envelope protein (WN-80E) with or without WN virus non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. A challenge dose of wild-type WN virus was administered to produce 40–100% mortality in the control hamsters. The recombinant antigen preparations containing WN-80E with or without WN NS1 gave similar results. Hamsters in both groups had a strong antibody response after immunization, and none of the aged or weanling animals became ill or developed detectable viremia after challenge with WN virus at 2 weeks after booster vaccination. However, mortality among the control animals (administered adjuvant without antigen) at 2 weeks after booster challenge was 40–60%. In hamsters rendered leukopenic after immunization, survival rates up to 80% were observed, and a low-level viremia was detected in the vaccinated and challenged hamsters. The survival rate was significantly ( < 0.05) higher in animals vaccinated with a higher dose of WN-80E than a lower dose. The addition of NS1 did not significantly affect survival after challenge. In contrast, all of the control animals that received adjuvant only developed a very high level of viremia, and the mortality rate was 100%. These findings indicate that the recombinant WN vaccines induced antibody in and afforded protection to young and aged hamsters and immunosuppressed hamsters.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.79.955
2008-12-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/79/6/0790955.html?itemId=/content/journals/10.4269/ajtmh.2008.79.955&mimeType=html&fmt=ahah

References

  1. Zeller HG, Schuffenecker I, 2004. West Nile virus: an overview or its spread in Europe and the Mediterranean basin in contast to its speread in the Americas. Eur J Clin Microbiol Infect Dis 23 : 147–156.
  2. Hayes EB, Komar N, Nasci RS, Montgomery SP, OLeary DR, ’ Campbell GL, 2005. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 11 : 1167–1173.
  3. Warner RD, Kimbrough RC, Alexander JL, Rush Pierce J Jr, Ward T, Martinelli LP, 2006. Human West Nile virus neuro-invasive disease in Texas, 2003 epidemic. Regional Differences Ann Epidemiol 16 : 749–755.
  4. Kumar D, Drebot MA, Wong SJ, Lim G, Artsob H, Buck P, Humar A, 2004. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant 4 : 1883–1888.
  5. Civen R, Villacorte F, Robles DT, Dassey DE, Croker C, Borenstein L, Harvey SM, Mascola L, 2006. West Nile virus infection in the pediatric population. Pediatr Infect Dis J 25 : 75–78.
  6. Braun LE, Tsuchida T, Spiegel H, 2006. Meningoencephalitis in a child complicated by myocarditis, quadriparesis and respiratory failure. Pediatr Infect Dis J 25 : 853–856.
  7. Smithburn KC, Hughes TP, Burke AW, Paul JH, 1940. A neurotropic virus isolated from blood of a native of Uganda. Am J Trop Med 20 : 471–492.
  8. Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P, 2006. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103 : 6694–6699.
  9. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR, 2006. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24 : 6392–6404.
  10. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD, 2008. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26 : 153–157.
  11. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS, 2007. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196 : 1732–1740.
  12. Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa AP, Humphreys T, Weeks-Levy C, 2007. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 25 : 414–423.
  13. Watts DM, Tesh RB, Siirin M, Travassos da Rosa AP, Newman PC, Clements DE, Ogata S, Coller BA, Weeks-Levy C, Lieberman MM, 2007. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25 : 2913–2918.
  14. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB, 2001. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7 : 714–721.
  15. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP, 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 8 : 1392–1397.
  16. Beaty BJ, Calisher CH, Shope RE, 1989. Arboviruses. Schmidt NJ, Emmons RW, editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Sixth edition. Washington, DC: American Public Health Association, 797–856.
  17. Sever JL, Castellano GA, Pelon W, Huebner RJ, Wolman F, 1964. Inactivation of the infectivity of viral hemagglutinating antigens with the use of betaprone (propiolactone). J Lab Clin Med 64 : 983–988.
  18. Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, Halevy M, 2000. A live attenuated WNV strain as a potential veterinary vaccine. Viral Immunol 13 : 401–410.
  19. Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B, 2004. Recombinant canarypox vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 18 : 221–230.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.79.955
Loading
/content/journals/10.4269/ajtmh.2008.79.955
Loading

Data & Media loading...

  • Received : 26 May 2008
  • Accepted : 12 Aug 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error